



MAYNE PHARMA APPOINTS CHIEF FINANCIAL OFFICER

29 September 2020, Adelaide Australia: Mayne Pharma Group Limited (ASX: MYX) has appointed Mr Peter Paltoglou as Chief Financial Officer. Peter has been serving as interim CFO since 20 March 2020.

Prior to the interim CFO role, Peter was Chief Development Officer with global responsibility for M&A, portfolio, strategic planning, business development and licensing activities and third-party partnerships.

Mayne Pharma's CEO, Mr Scott Richards said, "I am delighted to appoint Peter to the CFO role. He has proven his capability in the role as interim CFO, earning the trust of his peers, our Board and our investors. Peter knows Mayne Pharma well and brings deep knowledge and experience in corporate finance, financial planning, investor relations, strategy, mergers and acquisitions."

Given Peter's outstanding contribution in the interim CFO role over the past six months, the Board was pleased to support the CEO's recommendation to make the role permanent.

Peter has more than 20 years of experience in capital markets, corporate strategy and M&A. Prior to joining Mayne Pharma in August 2015, he was Managing Director of Investment Banking at Credit Suisse Emerging Companies in Australia.

For further information contact:

Lisa Pendlebury (VP Investor Relations & Communications)
+61 419 548 434, lisa.pendlebury@maynepharma.com

Authorised for release to the ASX by the Chairman

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on applying its drug delivery expertise to commercialise branded and generic pharmaceuticals, offering patients better and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to more than 100 clients worldwide.

Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems and these technologies have been successfully commercialised in numerous products that continue to be marketed around the world.

Mayne Pharma has two facilities based in Salisbury, Australia and Greenville, USA with expertise in the formulation of complex oral and topical dose forms including potent compounds, modified-release products and poorly soluble compounds.